Chairman:  Joe Pitts (PA-16)
Public health and quarantine; hospital construction; mental health; biomedical research and development; health information technology, privacy, and cybersecurity; public health insurance (Medicare, Medicaid) and private health insurance; medical malpractice and medical malpractice insurance; the regulation of food, drugs, and cosmetics; drug abuse; the Department of Health and Human Services; the National Institutes of Health; the Centers for Disease Control; Indian Health Service; and all aspects of the above-referenced jurisdiction related to the Department of Homeland Security.



Joe Pitts (PA), Chairman
Brett Guthrie (KY), Vice Chairman
Ed Whitfield (KY)
John Shimkus (IL)
Tim Murphy (PA)
Michael C. Burgess, M.D. (TX)
Marsha Blackburn (TN)
Cathy McMorris Rodgers (WA)
Leonard Lance (NJ)
Morgan Griffith (VA)
Gus Bilirakis (FL)
Billy Long (MO)
Renee Ellmers (NC)
Larry Bucshon (IN)
Susan Brooks (IN)
Chris Collins (NY)
Joe Barton (TX)
Fred Upton (MI) (Ex Officio)


Gene Green (TX), Ranking Member
Eliot L. Engel (NY)
Lois Capps (CA)
Jan Schakowsky (IL)
G. K. Butterfield (NC)
Kathy Castor (FL)
John Sarbanes (MD)
Doris O. Matsui (CA)
Ben Ray Lujan (NM)
Kurt Schrader (OR)
Joseph P. Kennedy, III (MA)
Tony Cardenas (CA)
Frank Pallone, Jr. (NJ) (Ex Officio)

September 25, 2014 | Blog Post

Health Care Law’s Implementation Costs On the Rise, Enrollment is Falling, and Security Concerns Remain with Still-Incomplete Website

September 23, 2014 | Press Release

Committee Continues to Closely Monitor the Situation

September 23, 2014 | ICYMI

A complete picture of enrollment in the president’s health care law has been difficult to come by.

September 22, 2014 | ICYMI

DeGette: “Addressing disease is not a partisan issue.”

September 22, 2014 | ICYMI

The 21st Century Cures initiative recently hosted its capstone D.C.

September 19, 2014 | Press Release

WASHINGTON, DC – The Subcommittee on Health, chaired by Rep. Joe Pitts (R-PA), today held a hearing to review the growing threat of antibiotic resistance and discuss ways to foster new drug development. Members heard from the Director of the Food and Drug Administration’s Center for Drug Evaluation and Research Dr.